129 related articles for article (PubMed ID: 8127063)
1. Tyrosinaemia type Ia without excess of urinary succinylacetone.
Biasucci G; Giuffré B; La Grutta S; Riva E
J Inherit Metab Dis; 1993; 16(6):1056-7. PubMed ID: 8127063
[No Abstract] [Full Text] [Related]
2. Urinary succinylacetone presence and delta-aminolaevulinic acid excretion in patients with type I tyrosinaemia during treatment.
Pronicka E; Mielniczuk Z; Rowińska E; Ksiazyk J; Szczygielska-Kozak M; Wieczorek E; Kulczycka H
Mater Med Pol; 1991; 23(2):136-8. PubMed ID: 1842600
[TBL] [Abstract][Full Text] [Related]
3. Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1.
Bain MD; Purkiss P; Jones M; Bingham P; Stacey TE; Chalmers RA
Eur J Pediatr; 1990 Jun; 149(9):637-9. PubMed ID: 2373116
[TBL] [Abstract][Full Text] [Related]
4. Hereditary tyrosinaemia type I: a long-term study of the relationship between the urinary excretions of succinylacetone and delta-aminolevulinic acid.
Schierbeek H; Beukeveld GJ; van Faassen H; van Spronsen FJ; Bijsterveld K; Venekamp-Hoolsema EE; Wolthers BG; Smit GP
J Inherit Metab Dis; 1993; 16(6):1034-40. PubMed ID: 8127053
[TBL] [Abstract][Full Text] [Related]
5. Determination of urinary succinylacetone by capillary gas chromatography.
Tuchman M; Whitley CB; Ramnaraine ML; Bowers LD; Fregien KD; Krivit W
J Chromatogr Sci; 1984 May; 22(5):211-5. PubMed ID: 6725495
[TBL] [Abstract][Full Text] [Related]
6. Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia.
Christensen E; Jacobsen BB; Gregersen N; Hjeds H; Pedersen JB; Brandt NJ; Baekmark UB
Clin Chim Acta; 1981 Nov; 116(3):331-41. PubMed ID: 7296896
[TBL] [Abstract][Full Text] [Related]
7. Genotyping of a case of tyrosinaemia type I with normal level of succinylacetone in amniotic fluid.
Poudrier J; Lettre F; St-Louis M; Tanguay RM
Prenat Diagn; 1999 Jan; 19(1):61-3. PubMed ID: 10073910
[TBL] [Abstract][Full Text] [Related]
8. Identification of 4,6-dioxoheptanoic acid (succinylacetone), 3,5-dioxooctanedioic acid (succinylacetoacetate) and 4-Oxo-6-hydroxyheptanoic acid in the urine from patients with hereditary tyrosinemia.
Lindblad B; Steen G
Biomed Mass Spectrom; 1982 Oct; 9(10):419-24. PubMed ID: 7171740
[TBL] [Abstract][Full Text] [Related]
9. Urinary excretion of deuterated metabolites in patients with tyrosinemia type I after oral loading with deuterated L-tyrosine.
Wadman SK; Duran M; Ketting D; Bruinvis L; van Sprang FJ; Berger R; Smit GP; Steinmann B; Leonard JV; Divry P; Farriaux JP; Cartigny B
Clin Chim Acta; 1983 May; 130(2):231-8. PubMed ID: 6872257
[TBL] [Abstract][Full Text] [Related]
10. Neonatal and prenatal diagnosis of hereditary tyrosinaemia.
King GS; MacKenzie F; Pettit BR
Lancet; 1983 Jun; 1(8336):1279. PubMed ID: 6134070
[No Abstract] [Full Text] [Related]
11. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B
Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656
[TBL] [Abstract][Full Text] [Related]
12. The antenatal diagnosis and aid to the management of hereditary tyrosinaemia by use of a specific and sensitive GC-MS assay for succinylacetone.
Pettit BR; MacKenzie F; King GS; Leonard JV
J Inherit Metab Dis; 1984; 7 Suppl 2():135-6. PubMed ID: 6434868
[No Abstract] [Full Text] [Related]
13. Liver transplantation in nine Spanish patients with tyrosinaemia type I.
Pérez-Cerdá C; Merinero B; Sanz P; Castro M; Gangoiti J; García MJ; Díaz M; Medina E; Ugarte M
J Inherit Metab Dis; 1995; 18(2):119-22. PubMed ID: 7564224
[No Abstract] [Full Text] [Related]
14. Persistent succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type I.
Tuchman M; Freese DK; Sharp HL; Whitley CB; Ramnaraine ML; Ulstrom RA; Najarian JS; Ascher N; Buist NR; Terry AB
J Inherit Metab Dis; 1985; 8(1):21-4. PubMed ID: 2581063
[TBL] [Abstract][Full Text] [Related]
15. Hematin therapy for the neurologic crisis of tyrosinemia.
Rank JM; Pascual-Leone A; Payne W; Glock M; Freese D; Sharp H; Bloomer JR
J Pediatr; 1991 Jan; 118(1):136-9. PubMed ID: 1986081
[No Abstract] [Full Text] [Related]
16. Impaired synthesis of taurine in a patient with tyrosinemia type I during the oral L-methionine loading test.
Valík D; Klusácek D; Pintera J
Clin Chim Acta; 1992 Sep; 210(3):227-9. PubMed ID: 1468144
[No Abstract] [Full Text] [Related]
17. Liver transplantation in a 23-year-old tyrosinaemia patient: effects on the renal tubular dysfunction.
Kvittingen EA; Jellum E; Stokke O; Flatmark A; Bergan A; Sødal G; Halvorsen S; Schrumpf E; Gjone E
J Inherit Metab Dis; 1986; 9(2):216-24. PubMed ID: 3091928
[TBL] [Abstract][Full Text] [Related]
18. Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation.
Tuchman M; Freese DK; Sharp HL; Ramnaraine ML; Ascher N; Bloomer JR
J Pediatr; 1987 Mar; 110(3):399-403. PubMed ID: 3546650
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia.
Berger R; Smit GP; Stoker-de Vries SA; Duran M; Ketting D; Wadman SK
Clin Chim Acta; 1981 Jul; 114(1):37-44. PubMed ID: 7249373
[TBL] [Abstract][Full Text] [Related]
20. Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts.
Manabe S; Sassa S; Kappas A
J Exp Med; 1985 Sep; 162(3):1060-74. PubMed ID: 3928801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]